Clinical Trials Browser

Phase 2 × Not yet recruiting × Myeloproliferative Disorders × Clear all

Myeloproliferative Disorders

NCT07572929 2026-05-07

PREeMPT

Phase 2 Not yet recruiting

450 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07468916 2026-05-06

Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia

Phase 2 Not yet recruiting

35 enrolled

MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Thrombocytosis, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT07528417 2026-04-22

MYELO-CAN:ABX

Phase 2 Not yet recruiting

75 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Neutropenia, Leukemia, Myeloid, Acute

NCT04451200 2020-11-17

BUSEQ

Phase 2 Not yet recruiting

82 enrolled

Myeloid

Myeloproliferative Disorders

Clinical Trials

Selinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative Myeloproliferative Neoplasms

PREeMPT

Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia

MYELO-CAN:ABX

BUSEQ